Literature DB >> 1346707

Azithromycin for cerebral toxoplasmosis.

C Farthing, M Rendel, B Currie, M Seidlin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1346707     DOI： 10.1016/0140-6736(92)90132-m

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  10 in total

1.  Evaluation of the efficacy of atovaquone alone or in combination with azithromycin against acute murine toxoplasmosis.

Authors:  S K Moshkani; A Dalimi
Journal:  Vet Res Commun       Date:  2000-04       Impact factor: 2.459

2.  Effects of 2',3'-dideoxyinosine on Toxoplasma gondii cysts in mice.

Authors:  M E Sarciron; P Lawton; C Saccharin; A F Petavy; F Peyron
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

Review 3.  Ocular involvement in toxoplasmosis.

Authors:  A Rothova
Journal:  Br J Ophthalmol       Date:  1993-06       Impact factor: 4.638

Review 4.  Azithromycin clinical pharmacokinetics.

Authors:  N J Lalak; D L Morris
Journal:  Clin Pharmacokinet       Date:  1993-11       Impact factor: 6.447

Review 5.  Management of toxoplasmosis.

Authors:  V S Georgiev
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

6.  Azithromycin versus Sulfadiazine and Pyrimethamine for non-vision-threatening toxoplasmic retinochoroiditis: a pilot study.

Authors:  Konstantinos Balaskas; Jean Vaudaux; Noémie Boillat-Blanco; Yan Guex-Crosier
Journal:  Med Sci Monit       Date:  2012-05

7.  Cryptosporidium and Toxoplasma Parasites Are Inhibited by a Benzoxaborole Targeting Leucyl-tRNA Synthetase.

Authors:  Andrés Palencia; Ru-Juan Liu; Maria Lukarska; Jiri Gut; Alexandre Bougdour; Bastien Touquet; En-Duo Wang; Xianfeng Li; M R K Alley; Yvonne R Freund; Philip J Rosenthal; Mohamed-Ali Hakimi; Stephen Cusack
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

8.  Targeting Toxoplasma gondii CPSF3 as a new approach to control toxoplasmosis.

Authors:  Andrés Palencia; Alexandre Bougdour; Marie-Pierre Brenier-Pinchart; Bastien Touquet; Rose-Laurence Bertini; Cristina Sensi; Gabrielle Gay; Julien Vollaire; Véronique Josserand; Eric Easom; Yvonne R Freund; Hervé Pelloux; Philip J Rosenthal; Stephen Cusack; Mohamed-Ali Hakimi
Journal:  EMBO Mol Med       Date:  2017-03       Impact factor: 12.137

9.  Licochalcone A: An effective and low-toxicity compound against Toxoplasma gondii in vitro and in vivo.

Authors:  Hongfei Si; Chunyan Xu; Jili Zhang; Xukun Zhang; Bing Li; Xuzheng Zhou; Jiyu Zhang
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2018-03-01       Impact factor: 4.077

Review 10.  Drug repurposing and human parasitic protozoan diseases.

Authors:  Katherine T Andrews; Gillian Fisher; Tina S Skinner-Adams
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2014-03-24       Impact factor: 4.077
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.